BSc (Hons), PhD, FBPhS, FRSB
Biography
Prof. RUDD John Anthony (陸臻賢) worked with Glaxo Group Research in the late 1980s to explore the potential use of the 5-HT3 receptor antagonist, ondansetron, to antagonize chemotherapy- and drug-induced emesis. He was also part of a team that mapped 5-HT3 receptor distribution in the human and ferret brainstem and first to show increases in of 5-HT in the plasma of patients receiving cisplatin-based chemotherapy. Pioneered the use of the ferret to model chemotherapy-induced acute and delayed emesis (now a gold standard model) and discovered that NK1 tachykinin antagonists could be used to prevent the acute and delayed phases of emesis induced by cisplatin: now NK1 tachykinin antagonists are a cornerstone of treatment for delayed emesis. He also collaborated with Helsinn on the development of the second generation 5-HT3 and NK1 receptor antagonists, palonosetron and netupitant, respectively. He has an ongoing interest in broad inhibitory antiemetic drugs and works with several leading pharmaceutical companies to aid drug development. He recently co-founded Gut Rhythm R&D (HK) Ltd., home to the proprietary ‘Gastro-Intestinal Pacemaker Activity Drug Database’, where he concurrently serves as a co-director and chief scientific officer. He is a Fellow of the British Pharmacological Society, Fellow of the Royal Society of Biology, and Fellow of the Royal Society of Medicine. Additionally, he is the founding vice president of the Hong Kong Laboratory Animal Sciences Society and serves as the Honorary Secretary of the Hong Kong Pharmacology Society.